In the nontumorous pituitary, GnRH stimulates the release and synthesis of LH and FSH by gonadotroph cells via the GnRH receptor (GnRH-R). Little is known, however, about expression of GnRH and GnRH-R messenger RNAs (mRNAs) in nontumorous pituitary tissue and in adenomas. To learn more about the distribution and regulatory roles of GnRH and its receptor, we investigated the expression of both GnRH and GnRH-R mRNAs in nontumorous human pituitary and in various types of pituitary adenomas using the RT-PCR, in situ hybridization, and in situ hybridization in combination with RT-PCR (in situ RT-PCR). Using RT-PCR, GnRH mRNA was found to be expressed in normal human pituitaries and in all types of adenomas. Similarly, GnRH-R mRNA was expressed in nontumorous human pituitaries and in most, but not all, adenomas. These included 5 gonadotroph adenomas, 6 null cell adenomas, 1 of 2 GH-producing tumors, and 1 of 2 ACTH-producing adenomas, but not in the 2 PRL-producing adenomas examined. In situ hybridization studies showed GnRH and GnRH-R mRNAs in all 3 nontumorous pituitaries and in 12 of 33 (36.4%) and 10 of 33 adenomas (30.3%), respectively. Using an indirect in situ RT-PCR technique to increase the sensitivity of the in situ localization, GnRH and GnRH-R mRNAs were detected in 29 (87.9%) and 25 (75.8%) of 33 adenomas, respectively. This is the first report of the localization of GnRH and GnRH-R mRNAs in individual pituitary adenoma cells using in situ RT-PCR. The frequent expression of GnRH and GnRH-R mRNAs in pituitary cells suggests that GnRH has autocrine/paracrine functions in nontumorous and neoplastic pituitary tissues. (J Clin Endocrinol Metab 
I
N THE NORMAL pituitary, GnRH is a hypothalamic hormone that stimulates the release and synthesis of LH and FSH by gonadotroph cells via the GnRH receptor (GnRH-R) (1, 2) . Although human pituitary adenomas have been shown to be monoclonal in nature (3, 4) , it still is not known whether hypothalamic hormones play a role in the genesis, growth, or differentiation of human pituitary adenomas. In vitro studies have shown that GnRH induces a significant increase in gonadotropins and/or gonadotropic hormone subunit release by human nonfunctioning pituitary adenomas (5, 6) . However, a significant number of pituitary adenomas are not under hypothalamic hormone regulation. In these adenomas, free gonadotropin subunit secretion has been observed after stimulation by GnRH (7, 8) . Abnormal responses to GnRH also have been observed in other types of adenomas. About 15-20% of acromegalic and Cushing's disease patients have abnormal increases in circulating GH and ACTH levels after GnRH administration (9, 10) .
The presence of GnRH-producing cells (11) and of GnRH messenger RNA (mRNA) (12) has been reported in rat anterior pituitary, which suggests that endogenously synthesized GnRH may be involved in local regulatory mechanisms. Alexander et al. (13) detected GnRH-R mRNA in human pituitary adenomas in vitro. In addition, using PCR techniques, Miller et al. (14) reported both GnRH and GnRH-R mRNAs in gonadotroph tumors, as well as in the normal human pituitary. Little is known, however, about GnRH and GnRH-R gene expression in other types of pituitary adenomas.
In situ hybridization is a technique useful in demonstrating gene expression in individual cells, but it is limited in its ability to detect low copy numbers of mRNAs. Recently, combined in situ hybridization and reverse transcription PCR (in situ RT-PCR) methods were applied to pituitary cells (15) . In the present report, we used this new technique to examine the expression of GnRH mRNA and GnRH-R mRNA in nontumorous human pituitaries and in various types of pituitary adenomas.
Materials and Methods

Tissues and cells
Three normal autopsy pituitaries, each obtained within 8 h of death from adult patients without endocrine abnormalities, and 33 pituitary adenomas were used in this study. Of patients with pituitary adenomas, 5 patients had GH-secreting tumors and acromegaly and elevated serum levels of GH and/or insulin-like growth factor, 4 had PRL-secreting adenomas with elevated serum PRL levels, three had ACTH-secreting tumors and Cushing's disease, and 21 had clinically nonfunctioning adenomas with no evidence of hormone hypersecretion and serum PRL levels less than 100 ug/L. Tumors, in which 25% or more of adenoma cells immunostained for FSH or LH ␤-subunits, were classified as gonadotropic adenomas. The remaining 12 tumors, which did not show hormone immunoreactivity or in which less than 25% of cells stained for gonadotropin ␤-subunits, were classified as null cell adenomas.
Tumor tissue fragments were frozen immediately at Ϫ70 C for the purpose of RNA extraction, immunohistochemistry, in situ hybridization, and in situ RT-PCR studies. As controls for RT-PCR, in situ hybridization, and in situ RT-PCR studies, two experimental cell lines were used: 1) the GH 3 rat PRL and GH-producing cell line (American Type Culture Collection, Rockwille, MD); and 2) the ␣T 3 -1 mouse pituitary gonadotroph cell line that produces ␣-subunit (Dr. P. Mellon, University of California, San Diego, CA). Both cell lines were maintained in DMEM (Life Technologies, Grand Island, NY) with 15% horse serum, 2.5% FBS, 5 g/mL insulin and 1% antibiotics. Cells were harvested for RNA extraction, and cell aliquots were affixed to slides by cytocentrifugation, fixed for 20 min in 4% paraformaldehyde at pH7.2, as previously reported (15) , and used for in situ studies.
Frozen sections of pituitary adenomas and nonneoplastic autopsy pituitaries were cut at 8 microns, fixed in 4% paraformaldehyde, washed in 2ϫ standard saline citrate (SSC), dehydrated in alcohol, and stored at Ϫ70 C. Mounted on silane-coated glass slides, these tissues were used for immunohistochemistry, in situ hybridization, and in situ RT-PCR experiments.
Oligonucleotide primers and probes
Oligonucleotide primers and hybridization probes were produced on a DNA oligonucleotide synthesizer (Applied Biosystems, Foster City, CA) (Table 1) . Both primers and probes for human GnRH (GenEMBL: X15215) and human GnRH-R (GenEMBL: L07949) were synthesized on the basis of published sequences (14, 16, 17) . Mouse GnRH (GenEMBL: M14872) and GnRH-R (GenEMBL: M93108) primers also were synthesized (18, 19) .
Solution PCR. Total RNA extraction was performed by the single-step method (TRIzol reagent kit, Life Technologies) from 3 nontumorous pituitaries and 17 cases of adenomas (20, 21) .
First-strand complementary DNA (cDNA) was prepared from total RNA by using a first-strand synthesis kit (Stratagene, La Jolla, CA). The RT reaction was performed at 37 C for 60 min in a final vol of 50 L with 5 g total RNA, 300 ng antisense primer, 1ϫ RT buffer, 1.0 mmol/L of each deoxyribonucleotide (dATP, dCTP, dTTP and dGTP), 40 U ribonuclease (RNase) inhibitor, and 50 U Moloney murine leukemia virus RT. The reaction product was then heated at 95 C for 5 min and immediately placed on ice.
The PCR was performed in 100-L final reaction volumes containing 5 L RT reaction product as template DNA, corresponding to cDNA synthesized from 500 ng total RNA, 1ϫ PCR buffer (Promega, Madison, WI), 1.5 mmol/L MgCl 2 , 0.2 mmol/L of each deoxynucleotide (Boehringer Mannheim, Indianapolis, IN), 300 ng of each sense and antisense primer for GnRH and GnRH-R, and 2.5 U Taq DNA polymerase (Promega). Programmable temperature cycling (Perkin-Elmer/Cetus 480, Norwalk, CT) was performed with the following cycle profile: 95 C for 5 min, followed by 94 C for 1 min, 60 C for 1 min, and 72 C for 2 min (30 cycles) for GnRH; and 94 C for 1 min, 62 C for 1 min, and 72 C for 2 min (35 cycles) for GnRH-R, respectively. After the last cycle, the elongation step was extended at 72 C for 10 min.
A 20-L aliquot of PCR product was analyzed by gel electrophoresis, using a 2% agarose gel, and was stained with ethidium bromide. PHx174 DNA/HaeIII digest (Boehringer Mannheim) was used as the standard. The separated PCR products were transferred to nylon membrane filters. Southern hybridization, with a single internal probe that hybridized to regions within the amplified sequences, was performed. Hybridization was performed with 1 ϫ 10 6 cpm/mL [ 33 P] deoxyadenosine diphosphate-labeled probe at 42 C for 18 h. After washing with 6ϫ SSC-0.1% SDS at 23 C for 20 min and at 42 C for 20 min, autoradiography was performed at Ϫ70 C with Kodak Omat-AR film (Eastman Kodak, Rochester, NY) with intensifying screens. In RT-PCR experiments, total RNAs from the aT 3 -1 and GH 3 cell lines were included as respective positive and negative controls for GnRH and GnRH-R.
Immunohistochemistry. Immunostaining for anterior pituitary hormones used the avidin-biotin peroxidase complex method (Vector Laboratories, Burlingame, CA). Primary antibodies were directed against the full spectrum of anterior pituitary hormones, including GH (1:1000 dilution), PRL (1:1000), LH␤ (1:500), FSH␤ (1:500), TSH␤ (1:1000) (all rabbit polyclonal and obtained from the National Pituitary Agency, Bethesda, MD), and rabbit polyclonal ACTH (1:1000) (Dako Corp., Santa Barbara, CA). The monoclonal antibody to ␣-subunit of glycoprotein hormones (1:250) was purchased from Biogenex (San Ramon, CA). Chromogranin A antibody (LK2H 10, 1:1000) was produced in our laboratory, as previously described (22) . The reaction products were visualized by 3,3Ј-diaminobenzidine tetrahydrochloride. 
In situ hybridization
A cocktail of four oligonucleotide probes for GnRH and for GnRH-R, internal to the amplified products from the primers, were labeled with digoxigenin-deoxyuridine 5-triphosphate (Boehringer Mannheim) by terminal deoxyribonucleotidyl transferase reaction, as previously reported (23) . The ISH procedure was performed as previously described (23, 24) . In brief, after deparaffinization, the sections were treated with 1 g/mL proteinase K (Boehringer Mannheim) at 23 C for 15 min, followed by heat treatment, hydrochloride treatment, acetylation, and then prehybridization. Thereafter, the sections were hybridized with 1 ng/L of the cocktail probe at 50 C for 18 h. After hybridization, immunodetection was performed using antidigoxigenin at a 1:500 dilution (Boehringer Mannheim). The reaction product was visualized by nitroblue tetrazolium salt and 5-bromo-4 chloro-3 indolyl phosphate (NBT-BCIP, Life Technologies). Control experiments were carried out using sense probes that had complementary sequences to one of the antisense probes.
In situ RT-PCR
The in situ RT-PCR technique was performed according to a threestep protocol previously described (15) . The same GnRH and GnRH-R primers and probes used for RT-PCR were employed for in situ RT-PCR. Briefly, tissue sections or aT 3 -1 cytospin cells were digested with 1 g/mL proteinase K at 23 C for 5 min and the enzyme was subsequently inactivated by heating to 80 C in PBS for 10 min. Then, after rinsing with H 2 O, the RT reaction was performed on the slides. The RT reaction mixture included: 10 mmol/L Tris-HCl, 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 10 mmol/L dithiothreitol, 0.2 mmol/L each of deoxyribonucleotide (Boehringer Mannheim), antisense oligonucleotide primer (1 g/ 100 L), RNasin (75U/100 L), and Superscript II RT (1000 U/100 L; Life Technologies). The reaction solution (50 L) was applied to each slide and was covered by glass coverslips. After a 2-h incubation at 42 C, the slides were washed in 2ϫ SSC, 1ϫSSC, 0.5ϫSSC, and water. For PCR, a total vol of 100 mL PCR solution with 10 mmol/L Tris-HCl, 50 mmol/L KCl, 2.5 mmol/L MgCl 2 , 1 mmol/L dithiothreitol, 0.2 mmol/L of each deoxynucleotide, sense and antisense primers (1 g each/100 L), and Taq DNA polymerase (10 U/100 L; Promega) was applied to each slide. The solution was sealed, using mineral oil (Sigma, St. Louis, MO), and then placed on the block of the thermocycler (OmniSlide; Hybaid, Middlesex, UK). After initial denaturation at 95 C for 5 min, PCR amplification was performed using a programmable cycle profile of 20 cycles for GnRH mRNA and 30 cycles for GnRH-R mRNA of amplification, with denaturing at 94 C for 2 min, annealing at 60 C for 1.5 min, extension at 72 C for 1.5 min, and final extension at 72 C for 10 min. After the PCR reaction, tissues were fixed in 4% paraformaldehyde for 5 min, followed by incubation in ethanol and a rinse in 2ϫ SSC. Slides were incubated with prehybridization solution at 23 C for 20 min and then hybridized overnight with labeled probes at 42 C. Immunodetection of the hybridization signals was performed as above. Control experiments performed included: 1) omission of RT or Taq polymerase; 2) omission of PCR primers; 3) pretreatment with RNase (Sigma), 100 g/mL in PBS at 37 C for 2 h before reverse transcription; and 4) analyzing the in situ RT-PCR amplified products from the supernatant by gel electrophoresis and Southern hybridization blotting (15) .
Grading of the in situ hybridization and in situ RT-PCR reactions was based on signal intensity as follows: Ϫ, negative; 1ϩ, weak; 2ϩ, moderate; 3ϩ, strong.
Results
Immunohistochemical findings
Immunohistochemical analyses showed 4 adenomas positive only for PRL; all 5 GH adenomas were positive for GH, with 4 of these cases also positive for PRL and for ␣-subunit of glycoprotein hormones (␣-SU). There were 3 ACTH adenomas that were positive only for ACTH; 9 gonadotroph (GTH) adenomas, all of which were positive for FSH␤ and ␣-SU, 4 of which also expressed LH␤. The 12 null cell adenomas were all diffusely positive for chromogranin A but had less than 25% of cells in the adenomas positive for FSH␤ or LH␤.
RT-PCR analysis
The results of RT-PCR are shown in Fig. 1 . Analysis of GnRH mRNA demonstrated that the expected 246-bp PCR product was detected by ethidium bromide staining in all 3 nontumorous pituitaries and in all 17 tumors studied. The expected 387-bp PCR product for GnRH-R mRNA was detected in all 3 nontumorous pituitaries and in 5 gonadotropin secreting adenomas, 6 null cell tumors, 1 of 2 GH-secreting adenomas, and 1 of 2 ACTH-secreting tumors analyzed. It was not seen, however, in 2 PRL-secreting adenomas. Southern hybridization with GnRH and GnRH-R internal probes showed strong bands for GnRH mRNA in all cases and for GnRH-R mRNA in 13 of the 17 adenomas. To further evaluate the absence of GnRH-R mRNA in PRL-secreting adenomas, the film was exposed for 10 days; the PRL adenomas remained negative like the negative control lanes (data not shown). The control RT-PCR experiment, using RNA extracted from ␣T 3 -1 gonadotroph cells, was positive for GnRH and GnRH-R mRNA, whereas RNA from the GH 3 cell line was negative for both (data not shown).
In situ hybridization and in situ RT-PCR
The in situ hybridization signal for GnRH mRNA was detected within the cytoplasm of both nontumorous pituitary cells and the ␣T 3 -1 cells. Compared with negative controls without probe or with sense probe, the signals were variably positive. A positive, but weak, signal for GnRH-R mRNA also was detected in normal pituitaries and in ␣T3-1 cells.
A positive hybridization signal for GnRH mRNA was detected in 12 of 33 adenomas (36.3%) by in situ hybridization (Table 2) . In most cases, the signal was relatively weak (1ϩ). A weak cytoplasmic signal for GnRH-R mRNA also was detected in the cytoplasm of 10 of 33 adenomas (30.3%). In situ hybridization controls with the sense probes were always negative.
When in situ RT-PCR was performed with ␣T 3 -1 cells, the hybridization signal for GnRH mRNA was amplified significantly. For the detection of GnRH-R mRNA, 30 cycles of PCR produced a stronger signal than did 20 cycles (Fig. 2) . Various controls for in situ RT-PCR were used, including analysis of the supernatant from the reaction. When the products in the supernatants were electrophoresed, after 20 or 30 cycles of amplification, bands of expected size were observed for GnRH mRNA and GnRH-R mRNA. Using mouse primer sets, in situ RT-PCR products of ␣T 3 -1 cells resulted in a stronger band than that seen when using human primers. Southern blot hybridization, with internal oligonucleotide probes labeled with 33 P, confirmed the specificity of the bands for GnRH and GnRH-R from the supernatant solutions (Fig. 3) . Although some nonneoplastic pituitary cells were positive in the slide preparation, no band was detected after 30 cycles of in situ RT-PCR. In situ RT-PCR products from a gonadotropin-producing adenoma showed strong bands for both GnRH and GnRH-R mRNAs. Other controls, including omission of PCR primers, RT, Taq polymerase, or RNase digestion before performing in situ RT-PCR, resulted in only background staining of tissue sections.
The results of in situ hybridization and in situ RT-PCR studies are shown in Tables 2 and 3 . GnRH and GnRH-R mRNAs were detected in 28 (84.8%) and 25 (75.8%) of the 33 adenomas, respectively. Although GnRH mRNA was found in all types of adenomas, GnRH-R mRNA was lacking in all 4 PRL-secreting adenomas examined. GnRH and GnRH-R mRNAs were detected in several adenomas that were negative by standard in situ hybridization ( Table 3 ). The signal intensity also was increased for GnRH-R mRNA; moderate (2ϩ) to strong (3ϩ) signals were observed in tissues that expressed only weak signal by in situ hybridization. A positive signal for GnRH mRNA was detected in most cells of all types of adenomas (Fig. 4) . A positive hybridization signal for GnRH-R was detected in the majority of cells in gonadotropin-secreting and null cell adenomas, whereas it was 
ISH, In situ hybridization; IS-RT-PCR, in situ RT-PCR grading; Ϫ, negative; 1ϩ, weak; 2ϩ, moderate; 3ϩ, strong. present in 10 to 50% of adenoma cells in GH and ACTH adenomas and not in PRL adenomas.
Discussion
Using solution RT-PCR and in situ RT-PCR analyses, we demonstrated GnRH and GnRH-R mRNAs in nontumorous and neoplastic pituitary cells. In this study, both GnRH and GnRH-R mRNAs were detected in nontumorous pituitaries. Detection of GnRH-containing cells (12) and of GnRH mRNA in the rat anterior pituitary has been reported (13) and suggests that endogenously synthesized GnRH may be involved in local regulatory mechanisms.
GnRH-R mRNA has been characterized in the pituitaries of several species (25, 26) . Alexander et al. (13) and Miller et al. (14) found GnRH and GnRH-R mRNAs in nontumorous and neoplastic human pituitaries by in vitro experiments and the PCR technique. These reports, however, did not investigate gene expression at the single-cell level.
In the present work, we applied in situ RT-PCR methods for the detection of GnRH and GnRH-R mRNAs. Using this technique, low amounts of mRNAs were detected in individual cells, and the signal intensity was found to be increased when compared with conventional in situ hybridization. An increase in the number of PCR cycles (from 20 to 30 cycles) increased the percentage of cases positive for GnRH-R mRNA, a finding consistent with the results of solution RT-PCR. In situ RT-PCR and in situ PCR both have been useful in the amplification and localization of RNA and DNA when present in low copy numbers within cells (27) (28) (29) . Specifically, this technique recently has been used to detect low copy numbers of mRNAs in endocrine cells (15, 21, 30) . One advantage of performing in situ RT-PCR with nonisotopic probes is the excellent resolution obtained with digoxigenin or biotin labeling after amplification of low-abundance mRNAs by the PCR technique. The approach was successful in the present study, because more cases were found to be positive for GnRH and GnRH-R by in situ RT-PCR than by simple in situ hybridization. Various controls for the in situ RT-PCR procedure were used, including analysis of the supernatant of the reaction. After 20 or 30 cycles of amplification and electrophoresis of the supernatant, the expected size bands for GnRH mRNA and GnRH-R mRNA were observed. In situ RT-PCR products from cultured ␣T 3 -1 cells, using mouse primers, resulted in stronger bands for GnRH and GnRH-R mRNA than when the human primers were used. Performance of various controls supported the specificity of our in situ RT-PCR studies. These consisted of omission of PCR primers, RT, Taq polymerase, and RNase digestion before performing in situ RT-PCR and resulted in no staining of the tissue sections. The GnRH-R mRNA analysis of the supernatant products from the normal pituitary was negative after 30 cycles. We have shown previously that the detection of bands by gel electrophoresis, using the supernatants from the in situ RT-PCR reaction, is dependent on the number of amplification cycles (15) . In the cases of normal pituitary, the supernatant was probably diluted by PRL cells and some other cells that did not express GnRH-R mRNA.
With the RT-PCR method, GnRH mRNA was detected in all 17 adenomas of various types, and GnRH-R mRNA in 15 of the 17. The high incidence of GnRH and GnRH-R gene expression in tumorous pituitaries suggests that locally produced hypothalamic hormones may play a role in the regulation of tumor cell growth. The presence of GnRH-R mRNA expression in some GH and ACTH-producing adenomas could explain the abnormal response to GnRH in some patients with acromegaly and Cushing's disease (9, 10). GnRH-R mRNA expression was found in all types of adenomas, except PRL-secreting adenomas, by both RT-PCR and in situ RT-PCR. Although our series include only a small number of tumors of varying type, it is of note that PRLsecreting adenomas did not express GnRH-R mRNA. In contrast, expression of GnRH-R mRNA also has been reported in ␣T 3 -1 mouse gonadotroph tumor cells (31) .
In the present study, all 5 gonadotropin-producing adenomas and 6 null-cell adenomas expressed GnRH-R mRNA. Miller et al., using the same upstream and downstream primer set, reported that 9 of 10 gonadotroph adenomas were positive for GnRH-R mRNA (14) and that only 6 of 10 adenomas were positive using another 5ЈGnRH primer set. One possible reason for the difference between these and our results may be the selection of adenomas studied. There also were differences in the PCR conditions. Miller et al. used a lower annealing temperature (at 53.2 C for GnRH and at 52.2 C for GnRH-R) for PCR. Despite the fact that a higher annealing temperature increases the specificity of the PCR reaction, our experiments resulted in more positive cases, even at a higher annealing temperature. Because, in the present study, the negative control using RNA from GH 3 cells was consistently negative for both GnRH and GnRH-R, contamination of RNA is highly unlikely.
Genetic studies carried out by X-chromosomal inactivation analysis revealed that the majority of pituitary adenomas are monoclonal in origin (3, 4) . Nonetheless, the hypothalamic hypothesis that pituitary tumors are secondary to hypothalamic dysregulation has not been completely resolved. Indeed, transgenic mouse studies, in which GHRH overproduction led to the development of pituitary adenomas in a time-dependent manner (32), do suggest that hypothalamic hormones play a role in adenoma development.
Evidence indicating that endogenous expression of hypothalamic hormone in the pituitary has been accumulating in recent years. A number of hypothalamic neuropeptides known to influence anterior pituitary secretion, such as GHRH, TRH, CRH, vasoactive intestinal polypeptide, neuropeptide Y, substance P, and galanin have been shown to be synthesized by pituitary cells (33) (34) (35) (36) (37) (38) (39) . With regard to pituitary adenomas, it is of note that using RT-PCR methods, GHRH gene expression has been reported in all somatotroph adenomas but is not evident in either nonfunctioning or normal anterior pituitary (40) . Furthermore, using RT-PCR, CRH transcript has been found in about 20% of pituitary tumors of different types (41) . The finding of various releasing hormones in pituitary adenomas sheds light on recent observations about pituitary adenoma with neuronal choristoma lesions (42) (43) (44) . Such lesions, which consist of varying proportions of pituitary adenoma, usually GH cell adenoma, and neurons were long considered manifestations of ectopic hypothalamic neurons with induced adenoma (42, 43) . The recent morphologic demonstration of cells transitional between adenoma cells and neurons (44) suggests a metaplastic origin of the neurons. This interpretation is supported by the present work and that of Wakabayashi et al. (40) , which conclusively demonstrated releasing hormones in morphologically typical adenomas devoid of neuronal elements.
The expression of many hypothalamic hormone receptor genes by pituitary cells also has been demonstrated. For instance, the pharmacologic and biochemical characteristics of dopamine D 2 receptors in PRL-secreting adenomas have been investigated extensively (45) . Similarly, somatostatin (SS) receptors (SSTRs), which includes five separate subtypes, also have been detected in the pituitary; and SSTR 2 and SSTR 5 mRNA have been demonstrated (46) . Given the therapeutic importance of bromocriptine and SS analogs binding to these receptors (47) , the presence of these receptors is of clinical interest. Expression of GHRH-R mRNA and TRH-R mRNA in human pituitary and pituitary adenomas also has been reported (48) .
The processes of GnRH-producing, hypothalamic neurons terminate not only in the median eminence but also on other GnRH-producing nerve cells. It is no surprise, therefore, that GnRH-producing neurons express abundant GnRH-R, an arrangement suggesting that autocrine regulation of GnRH release does occur within the brain (49) . Thus, it seems that GnRH acts as a neurohormone, neurotransmitter, or neuromodulator, as well as a local hormone in the brain. It has been proposed that pituitary tumors can produce a number of substances that may have secretory, differentiating, and proliferative functions (50) . Hypothalamic hormones may have just such specific roles, acting not only as classical releasing hormones, but also as neuromodulators.
Although GnRH-R has been detected in the ␣-subunit producing ␣T 3 -1 cell line (31, 51) , expression of GnRH by these oncogenically transformed cells has not been detected previously by in situ RT-PCR or other in situ methods. On the other hand, our study showed that ␣T 3 -1 cells express both GnRH and GnRH-R mRNAs by RT-PCR. Similar results were obtained using cultured cells by in situ RT-PCR. These observations suggest that autocrine/paracrine regulatory mechanisms may be ongoing in these cells, as well as in normal and neoplastic human pituitary tissues.
The biological significance of GnRH expression by all pituitary adenomas and of GnRH-R expression by most tumors is uncertain. Recent studies, using endometrial carcinoma cell lines, found low levels of GnRH and GnRH-R mRNAs, but secretion of GnRH and functional receptor activity were uncommon findings in these cell lines (51) . Thus, the functional significance of GnRH and GnRH-R mRNA expression by pituitary adenomas will have to be investigated further by functional studies in vitro.
In conclusion, the presence of GnRH and GnRH-R mRNA in various types of adenomas, as detected by in situ techniques, indicates that endogenous production of the hypothalamic hormone GnRH and its receptor in pituitaries may have a role in autocrine/paracrine regulation. Further investigations will be needed to clarify the mechanisms of such regulation and the possible role of hypothalamic hormones and their receptors in the genesis, growth, and differentiation of pituitary adenomas.
